


Vaping: Panic, Proportion, and the Numbers We Ignore

The cultural script around vaping has hardened quickly: sleek pods in school bathrooms, disposables in playground trash bins, the public-health community ringing the same alarms it once rang for cigarettes. Policymakers have largely followed that script, folding vapor into the architecture of tobacco control without pausing to ask whether the risks are truly comparable. Yet the science we already have tells a different story. Combustion is the killer. Aerosol is not. For smokers, switching is less a lateral move than a steep descent down the risk ladder.

China's manufacturing ecosystem pushed the hardware into the world, and Western governments responded by treating it as if it were just another cigarette. That reflex may be politically convenient, but it obscures the one fact that matters most: the magnitude of harm reduction is so large that, in almost every domain where we can measure it, vaping and smoking barely belong on the same axis.

Vaping vs Smoking - Relative Attributable Risk of Outcomes



What the Numbers Tell Us

The deltas here are too large to dismiss as marginal. Lung cancer risk collapses to nine percent of that of smoking. COPD drops by two-thirds. Bystander hazard falls to a rounding error. Even all-cause mortality—the hardest outcome to move—is cut in half. Cardiovascular disease and pregnancy outcomes are the outliers, where nicotine itself carries persistent risk. But the dominant picture is not “two risky products, equally bad.” It is one catastrophic product and one that, while not benign, is dramatically safer.

For smokers, that difference is not academic. It is the difference between a near-certain chronic disease and a plausible return to baseline health. For never-smokers, particularly adolescents, the calculus is reversed: you are starting down a road you never needed to walk. The public-health challenge is to hold both of these truths at once, without letting the panic about youth initiation erase the life-saving potential of adult substitution.

Policy Review and Recommendations

American regulators have mostly refused to make that distinction. By treating e-cigarettes as if they were just another tobacco product, the FDA's pre-market pathway has blocked lower-risk, testable devices while the illicit disposable flood—largely manufactured in Shenzhen—has become the default. Adults are left without reliable access to proven cessation tools; teenagers have little trouble finding neon-colored imports at corner shops. This is not regulation. It is paralysis disguised as prudence.

A proportionate framework would look different:

1. Separate vaping from smoking in law. Regulate on emissions, not on ancestry. Set ceilings for aldehydes, nitrosamines, metals, and CO. Devices that meet them get fast-tracked. Those that don't are barred.
2. Protect youth with enforcement, not symbolism. Real-time ID verification at point of sale, importer liability, track-and-trace serialization. Retail bans alone miss the upstream supply chains where disposables actually flow.
3. Price in risk honestly. Keep cigarette taxes high. Keep vape taxes low but nonzero—enough to dull impulse uptake in minors without erasing the economic incentive for smokers to switch. Add a deposit or recycling fee to deal with disposable e-waste.
4. Integrate vaping into cessation care. Let clinicians recommend approved vapes, paired with behavioral support, covered like any other therapy. By twelve-month abstinence, the odds nearly double; that should be counted as a feature, not a loophole.
5. Draw bright lines where the risk is real. Pregnancy: absolutely contraindicated. Youth: off-limits. But on secondhand exposure, the numbers are unambiguous—vaping is not smoke. Equating them under clean-air laws is not caution, it is category error. Reserve restrictions for the few places where bystander risk actually matters—pediatric wards, neonatal units—not as a blanket symbolic gesture.

The point is not to deregulate. It is to regulate *proportionately*, in a way that matches the shape of the harm. Adults who smoke should have every incentive and every channel to switch. Youth should face the sharp edge of enforcement if they try to start. Bystanders should be protected where the evidence says they are at risk, not where political optics demand symmetry.

Closing

What the table shows, more clearly than any speech or press release, is that vaping and smoking do not belong in the same policy bucket. Treating them as twins is not caution, it is negligence of another kind—negligence toward the lives that could be extended if switching were made easier, and toward the credibility of public health itself. The unseen cost of panic is not just bad law. It is trust squandered when the public eventually notices that the numbers never lined up with the story.

Relative Risk of Vaping vs Smoking

Domain / Outcome	Smoker	Vaper	Relative Risk
Pulmonary disease (COPD, chronic bronchitis)	27.5%	10%	36%
Lung cancer (lifetime incidence)	17.5%	1.5%*	9%
Cardiovascular disease (MI or stroke)	42.5%	34%	80%
Other cancers (oral, bladder, esophageal)	9%	1.5%*	17%
All-cause mortality (RR vs baseline)	2.5×	1.2×	48%
Secondhand exposure (bystander CHD excess risk)	+25	+2*	8%
Oral health (periodontitis, tooth loss)	20%	10%*	50%
Pregnancy adverse outcomes (LBW, stillbirth, SIDS risk)	15%	12%*	80%
Cessation success (12-mo validated abstinence)	7%	13%	186%

*Projected from biomarkers or early cohort data, not long-term incidence.
Midpoints used when ranges available; vaper values from biomarker reductions and early cohorts.

References

- [1] Polosa R, et al. Health effects in COPD smokers who switch to electronic cigarettes: a 3-year follow-up study. *Int J Chron Obstruct Pulmon Dis*. 2018;13:2533-2542. <https://doi.org/10.2147/COPD.S161138>
- [2] Shahab L, et al. Nicotine, Carcinogen, and Toxin Exposure in Long-Term E-Cigarette and Nicotine Replacement Therapy Users. *Ann Intern Med*. 2017;166:390–400.
- [3] Royal College of Physicians. Nicotine without smoke: tobacco harm reduction. London: RCP, 2016.
- [4] Benowitz NL, Fraiman JB. Cardiovascular effects of electronic cigarettes. *Nat Rev Cardiol*. 2017;14(8):447-456.
- [5] NASEM (National Academies of Sciences, Engineering, and Medicine). Public Health Consequences of E-Cigarettes. Washington, DC: National Academies Press; 2018.
- [6] Stephens WE. Comparing the cancer potencies of emissions from vapourised nicotine products. *Tob Control*. 2018;27(1):10-17.
- [7] Goniewicz ML, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. *Tob Control*. 2014;23(2):133-139.
- [8] Holliday R, et al. Vaping and oral health: a scoping review. *J Dent*. 2021;112:103735.
- [9] McDonnell BP, et al. Electronic cigarettes and pregnancy: a systematic review of safety and health outcomes. *Nicotine Tob Res*. 2020;22(9):1670-1680.
- [10] Hajek P, et al. A randomized trial of e-cigarettes versus nicotine replacement therapy. *N Engl J Med*. 2019;380:629-637.
- [11] Public Health England. Evidence review of e-cigarettes and heated tobacco products 2018. London: PHE, 2018.
- [12] U.S. Surgeon General. E-Cigarette Use Among Youth and Young Adults: A Report of the Surgeon General. U.S. DHHS, 2016.
- [13] McNeill A, et al. Vaping in England: evidence update including vaping for smoking cessation, February 2021. Public Health England.
- [14] U.S. Surgeon General. The Health Consequences of Smoking—50 Years of Progress. U.S. DHHS, 2014.